MediciNova Receives Notice of European Patent Allowance for Treating Progressive MS
MediciNova (NASDAQ: MNOV) today announced that it has received a Notice of Allowance from the European Patent Office for a pending patent application which covers the use of ibudilast (MN-166) for the treatment of progressive forms of multiple sclerosis (MS). MN-166 is the company's drug development candidate for certain neurological conditions, including progressive MS, drug addiction and pain.
A patent maturing from this allowed patent application is expected to expire no earlier than early 2029 and covers a method of treating primary progressive MS (PPMS) or secondary progressive MS (SPMS) by administering ibudilast either alone or in combination with other drugs. The patent application is based upon clinical investigations conducted by MediciNova and collaborating researchers that showed an apparent disease-modifying benefit in which brain volume loss, or brain atrophy, commonly associated with disease progression, was reduced by oral administration of ibudilast to a group of MS patients including some subjects with progressive MS, in a dose-related fashion over at least a 10-month treatment period.
"We are very pleased with this positive step